原位与体外开窗支架腔内修复主动脉弓病变的中期结果
本研究回顾性比较了原位开窗与体外开窗支架行TEVAR治疗主动脉弓病变的中期结果。共纳入46例患者,每组23例,技术成功率97.8%,30天死亡率2.2%。中位随访40.8个月,两组总生存率、分支动脉通畅率及再干预率均无显著差异。
要点
- 原位与体外开窗支架治疗主动脉弓病变的早期和中期结果相当。
- 技术成功率97.8%,围术期卒中发生率6.7%,脊髓缺血2.2%。
- 48个月总生存率原位组95.5% vs 体外组74.2%,无统计学差异(p=0.59)。
核心结论
- 对于主动脉弓病变患者,原位开窗与体外开窗技术显示出相当的早期和中期结果。
研究设计与样本
- 共46例患者(平均年龄59岁;男性40例),原位开窗组和体外开窗组各23例。
主要发现
- 技术成功率为97.8%(45/46),1例患者在30天内死于严重肺部感染。
- 围术期主要不良事件包括卒中3例(6.7%)和脊髓缺血1例(2.2%)。
- 中位随访40.8个月(IQR=57),1个月和48个月的全因总生存率估计分别为97.8%(SE=2.2%)和84.5%(SE=6.7%)。
- 48个月总生存率原位组为95.5%(SE=4.4%),体外组为74.2%(SE=11.7%),Log-rank检验无显著差异(p=0.59)。
- 分支动脉总体一期通畅率在1个月和48个月分别为97.8%(SE=2.2%)和92.2%(SE=4.4%);48个月时原位组87.9%(SE=8.2%),体外组95.7%(SE=4.3%)(p=0.51)。
临床怎么用
- 原位开窗与体外开窗技术均可用于主动脉弓病变的腔内修复,中期结果相当。
- 选择开窗方式时可综合考虑患者解剖条件和技术可行性,两种方法均可作为选项。
局限性
- 单中心回顾性研究,样本量较小(46例)。
- 需要更多患者和更长随访时间来进一步验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) with fenestration technology for reconstruction of the aortic arch branches has been used in patients with aortic arch pathologies. However, the outcomes of comparisons between the 2 reconstruction methods are rarely reported. This study sought to compare and clarify the midterm outcomes between in situ and in vitro fenestrated stent-grafts for endovascular repair of aortic arch pathologies. METHODS: Between July 2016 and December 2023, the patients with aortic arch pathologies, who underwent TEVAR with in situ and in vitro fenestration grafts, were retrospectively evaluated. Endpoints included technical success, 30-day mortality, major adverse events, secondary interventions, target vessel patency, and overall survival. RESULTS: A total of 46 patients (mean age 59 years; 40 males) with aortic arch pathology were included, each group (in situ and in vitro fenestration) with 23 cases. Technical success was 97.8% (45/46), and 1 patient died from severe pulmonary infection within 30 days. Perioperative major adverse events included stroke (n=3; 6.7%), spinal cord ischemia (SCI) (n=1; 2.2%). During a median follow-up of 40.8 months (IQR=57). The estimated all-cause overall survival rate was 97.8% (standard error [SE]=2.2%) and 84.5% (SE=6.7%) at 1 month and 48 months, respectively. The survival rate in the in situ group at 48 months was 95.5% (SE=4.4%) and the in vitro group was 74.2% (SE=11.7%). Log-rank test showed no significant difference (p=0.59). The overall branch arteries' primary patency was 97.8% (SE=2.2%) and 92.2% (SE=4.4%) in 1 month and 48 months. There was no significant difference between the 2 groups at 48 months (87.9% [SE=8.2%] for the in situ group, 95.7% [SE=4.3%] in the in vitro group [p=0.51]). The estimated freedom from secondary intervention was 100%, 90.2% (SE=4.7%), 84.0% (SE=6.1%), and 86.7% (SE=5.6%), at 1 month, 1 year, and 4 years. At 4 years, there was no significant difference in the estimated freedom from reintervention between the 2 groups (77.0% [SE=10.4%] for in situ group and 95.5% [SE=4.4%] in the in vitro group [p=0.33]). CONCLUSION: For patients with aortic arch pathologies, in situ and in vitro fenestration techniques revealed comparable early and midterm results. Further evaluation of more patients with longer follow-up is needed to substantiate these results.Clinical ImpactOur single-center retrospective cohort study conducted a comparative analysis of in-situ fenestration versus in-vitro fenestration techniques in patients with aortic arch pathologies.Comparative studies between the two approaches are still limited. Our results provide a basis for the selection of in-situ or in-vitro fenestration techniques for endovascular repair of aortic arch lesion.
引用
- Miao S, Gui L, Chen H, et al. Midterm Outcomes of In Situ and In Vitro Fenestrated Stent-Grafts for Endovascular Repair of Aortic Arch Pathologies. J Endovasc Ther. 2025. PMID: 41222305. doi:10.1177/15266028251384920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。